These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 35222385

  • 1. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
    Basu B, Angeletti A, Islam B, Ghiggeri GM.
    Front Immunol; 2022; 13():805697. PubMed ID: 35222385
    [Abstract] [Full Text] [Related]

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM.
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.
    Conversano E, Debiec H, Colucci M, Emma F, Ronco P, Vivarelli M.
    Pediatr Nephrol; 2024 Jan; 39(1):305-308. PubMed ID: 37466865
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM.
    Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM.
    Clin J Am Soc Nephrol; 2016 Apr 07; 11(4):710-20. PubMed ID: 26585985
    [Abstract] [Full Text] [Related]

  • 8. Ofatumumab for the treatment of childhood nephrotic syndrome.
    Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B.
    Pediatr Nephrol; 2017 May 07; 32(5):835-841. PubMed ID: 28213687
    [Abstract] [Full Text] [Related]

  • 9. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P, Bonanni A, Ghiggeri GM.
    BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
    [Abstract] [Full Text] [Related]

  • 10. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G.
    Pediatr Nephrol; 2017 Jan 17; 32(1):181-184. PubMed ID: 27687621
    [Abstract] [Full Text] [Related]

  • 11. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R, Rawlings C, Mon SY, Jefferis J, John GT.
    BMC Nephrol; 2022 Apr 07; 23(1):134. PubMed ID: 35392837
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
    Peters HP, van de Kar NC, Wetzels JF.
    Neth J Med; 2008 Nov 07; 66(10):408-15. PubMed ID: 19011266
    [Abstract] [Full Text] [Related]

  • 13. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, Conti G, Buemi M, Santoro D.
    Expert Opin Investig Drugs; 2018 Nov 07; 27(11):839-879. PubMed ID: 30360670
    [Abstract] [Full Text] [Related]

  • 14. Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child.
    Solomon S, Zolotnitskaya A, Del Rio M.
    Pediatr Transplant; 2019 Jun 07; 23(4):e13413. PubMed ID: 30973669
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rescue with obinutuzumab and daratumumab as combined B cell/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence.
    Randone P, Sanna E, Dolla C, Gallo E, Mingozzi S, Tarragoni R, Torazza MC, Niarchos A, Mella A, Manzione AM, Barreca A, Deambrosis I, Giraudi R, Biancone L.
    Am J Transplant; 2024 Oct 07; 24(10):1896-1900. PubMed ID: 39029875
    [Abstract] [Full Text] [Related]

  • 19. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
    Colucci M, Angeletti A, Zotta F, Carsetti R, Lugani F, Ravà L, Ravani P, Emma F, Ghiggeri GM, Vivarelli M.
    Kidney Int; 2023 Sep 07; 104(3):577-586. PubMed ID: 37385541
    [Abstract] [Full Text] [Related]

  • 20. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A, Piecha G, Więcek A.
    Transplant Proc; 2016 Nov 07; 48(9):3092-3094. PubMed ID: 27932154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.